Cowen & Co. Maintains Their Buy Rating on Esperion (ESPR)
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Esperion (ESPR) yesterday and set a price target of $80. The company’s shares closed yesterday at $39.02, close to its 52-week low of $36.06.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.2% and a 40.0% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $88.29, representing a 126.3% upside. In a report released yesterday, Northland Securities also maintained a Buy rating on the stock with a $65 price target.
See today’s analyst top recommended stocks >>
Based on Esperion’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $87.38 million. In comparison, last year the company had a GAAP net loss of $45.73 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).